Guangdong-based Jianke Pharmaceutical, operator of B2C pharmaceutical e-commerce site Jianke.com, has announced the acquisition of Wuhan-based Xiong Chu Hospital.
The future of internet healthcare relies on a physical presence for long-term growth, said Jianke CEO Xie Fangmin, who further revealed plans to build 6 hospitals across China and partner with hospitals in Beijing, Guangdong, Hubei, Chongqing, and Hainan. The physical hospitals will serve as the basis for Jianke's Internet Hospital, and help accelerate the launch of a chronic disease management project.
Wuhan Xiong Chu Hospital combines healthcare, education, research, prevention, and health maintenance in a single hospital that integrates Western and Traditional Chinese Medicine. "Compared with other cities, first-tier cities such as Guangzhou and Wuhan have superior medical resources," said Xie. Jianke has operations centers in both cities, which will facilitate integration of those medical resources.
Editor's Note: This news follows an announcement from Jianke yesterday that it had obtained a class A online pharmaceuticals transaction services license, allowing the company to operate a third-party online B2B drug trading platform. Jianke now possesses class A, B, and C online pharmaceuticals transaction licenses. For more information on this topic, please see Jianke Secures Online Third-party B2B Drug Trading License, MD 6/13/17 issue.